Four patients with t(11;14) MM with CCND1-IGH fusion confirmed by FISH who were relapsed or refractory to prior therapies were able to achieve responses with the combination of selinexor and venetoclax, with two patients achieving a VGPR. This evidence concerns the gene CCND1 and Miyoshi myopathy.